HOOKIPA Pharma Inc.
HOOK evidence brief
What we can confirm
- BioSniper Score:
- 7.3 / 10
- Market Cap:
- $14.2M
- Lead Asset:
- eseba-vec (Phase 2)
What it means
What to watch
Prepared research question
What matters most for HOOK—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · HOOK
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies based on its proprietary arenavirus platform, with a current emphasis on oncology and infectious disease programs.
Key risk: Going concern uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$14.2M
Cash Runway
—
Lead Asset
eseba-vec (Phase 2)
Next Catalyst
—
Tracking 5 pipeline candidates · 4 clinical trials for HOOKIPA Pharma Inc..
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies based on its proprietary arenavirus platform, with a current emphasis on oncology and infectious disease programs.
- Cash and equivalents of $40.5M as of 2025-03-31 [sec].
- Total revenue of $2.0M for the quarter ended 2025-03-31 [sec].
- Net loss of $15.4M for the quarter ended 2025-03-31 [sec].
- Shareholders' equity of $51.2M as of 2025-03-31 [sec].
- Substantial doubt about the company's ability to continue as a going concern within one year of the financial statement issuance date [sec_mda · as of 2025-05-15].
What works
- The company has collaboration agreements with Gilead and Roche, which provide upfront, milestone, and initiation payments to support development [sec_mda · as of 2025-02-28].
- HOOKIPA's arenavirus platform is designed to generate potent T-cell responses, which may offer a differentiated approach in immunotherapy [sec_mda · as of 2025-05-15].
What to weigh
- The company has a history of net losses and expects to continue incurring losses, with no product revenue expected until regulatory approval and commercialization [sec_mda · as of 2025-02-28].
- There is substantial doubt about HOOKIPA's ability to continue as a going concern for one year after the issuance of its financial statements [sec_mda · as of 2025-05-15].
- All product candidates require substantial additional development time and resources, with no guarantee of successful completion or regulatory approval [sec_mda · as of 2025-05-15].
From the filings
Quoted directly from source documents.
Substantial doubt about going concern
“there is substantial doubt regarding our ability to continue as a going concern for a period of one year after the issuance date of the condensed consolidated financial statements accompanying this Quarterly Report on Form 10-Q.”
SEC MD&A · May 15, 2025
Cash position as of December 31, 2024
“As of December 31, 2024 we had cash, cash equivalents and restricted cash of $39.9 million.”
SEC MD&A · February 28, 2025
No product revenue until regulatory approval
“We do not expect to generate revenue from any product candidates that we develop until we obtain regulatory approval for one or more of such product candidates, if at all, and commercialize our products or enter into additional collaboration agreements with third parties.”
SEC MD&A · February 28, 2025
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue as a going concern within one year [sec_mda · as of 2025-05-15].
- No product revenue — No revenue from product sales expected until regulatory approval and commercialization [sec_mda · as of 2025-02-28].
- Need for additional funding — Requires additional funding to pursue clinical and preclinical development [sec_mda · as of 2025-05-15].
- Clinical trial uncertainty — Uncertainty in successful completion of preclinical studies and clinical trials [sec_mda · as of 2025-05-15].
What to watch
- Ability to secure additional financing to address going concern [sec_mda · as of 2025-05-15].
- Progress of clinical trials for lead product candidates [sec_mda · as of 2025-05-15].
- Updates on collaboration agreements with Gilead and Roche [sec_mda · as of 2025-02-28].
Sources: SEC MD&A · Generated August 14, 2026 · How we verify sources →
Run HOOKIPA Pharma Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available HOOKIPA Pharma Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 2
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 0.4%
- Days to cover
- 0.6
- Shares short
- 35,804
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
HOOK short interestGovernance
Frequently asked questions
What is the AI investment thesis for HOOKIPA Pharma Inc.?
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies based on its proprietary arenavirus platform, with a current emphasis on oncology and infectious disease programs.
What is HOOKIPA Pharma Inc.'s lead drug candidate?
HOOKIPA Pharma Inc.'s most advanced tracked candidate is eseba-vec (Phase 2) for Human Papillomavirus 16-positive (HPV16+) head and neck cancers.
Who is the CEO of HOOKIPA Pharma Inc.?
Dr. Malte Peters M.D. is the chief executive officer of HOOKIPA Pharma Inc. (HOOK).
Where is HOOKIPA Pharma Inc. headquartered?
HOOKIPA Pharma Inc. (HOOK) is headquartered in New York, NY, United States.
What therapeutic areas does HOOKIPA Pharma Inc. focus on?
HOOKIPA Pharma Inc. develops therapies across Oncology, Immunology, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.